You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on lung cancer.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
The serum-based proteomic test gauges a pre-treatment immune profile that has shown in retrospective studies to identify patients who are likely to respond well to anti-PD-1 therapy.
The agency approved the test for use across solid tumors and with multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.
However, the lack of biomarker-specific treatment data kept researchers from definitively concluding that precision oncology treatments were behind an accelerated rate of NSCLC mortality decline.
GenPro will use its EpiMarker machine-learning platform to identify a network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of drug response.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
The agent has been approved for both treatment-naïve and previously treated patients whose tumors have a mutation that leads to MET exon 14 skipping.
Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.
The company will study its investigational drug rigosertib in combination with Opdivo in patients with KRAS-mutated lung cancer.